Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitor
In 2019 Targovax reported encouraging data from part 1 of a trial in PD-1 checkpoint refractory melanoma. This trial examines how ONCOS-102 reactivates the immune system of patients that have progressed on checkpoint inhibitor treatment. The aim is to trigger relevant T-cell production and infiltration into the tumor so that patients who have become refractory can benefit from retreatment with the checkpoint inhibitor. Data from part 2 of this trial is expected later in 2020.